Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.
Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
People with certain inflammatory immune conditions affecting the joints, bowel and skin, such as rheumatoid arthritis, may have been more at risk of dying or needing hospital care if they got COVID-19 before vaccination compared with the general population, according to a new study published in The Lancet Rheumatology.
In a recent study posted to the medRxiv* preprint server, researchers assessed the impact of coronavirus disease 2019 (COVID-19) on the prescribing safety of high-risk medications on a national scale in England.
A new study addresses the relationship between SARS-CoV-2 to the metabolism of one-carbon molecules in the host, suggesting new therapeutic pathways.
Despite guidelines that call for early and aggressive treatment of rheumatoid arthritis, a new study suggests many older adults are not prescribed disease-modifying medications for their inflammatory autoimmune disease.
If a cancer patient tests positive for COVID-19, are they more likely to become hospitalized from the disease?
Two treatments that have been shown to be ineffective against COVID-19—hydroxychloroquine and ivermectin—were more heavily prescribed in the latter part of 2020 in U.S. counties with a higher Republican vote share in the 2020 presidential election, according to a new research letter co-authored by researchers from Harvard T.H. Chan School of Public Health.
In a recent study posted to the medRxiv* preprint server, researchers evaluated if folic acid or methotrexate use impacts the risk of coronavirus disease 2019 (COVID-19) diagnosis or associated mortality in the United Kingdom (UK).
A recent study posted to the medRxiv* preprint server investigated the risk of severe/fatal coronavirus disease 2019 (COVID-19) in patients treated with immunosuppressants for inflammatory rheumatic diseases (IRD).
Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery will be reported at the 2022 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (GU ASCO) on February 18, 2022.
New research posted to the medRxiv* preprint server finds patients with immune-mediated inflammatory diseases undergoing anti-TNF therapy had the greatest reduction of antibody levels three months after vaccination. In addition, they had weaker neutralization responses towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.
The autoimmune disorder rheumatoid arthritis has been associated with a lower risk of Parkinson's disease (PD) in previous studies, with antirheumatic drugs as one possible explanatio
A team of researchers assessed the immune response after administering a SARS-COV-2 vaccine in immuno-compromised subjects who are potentially at an increased risk to experience severe COVID-19 and inadequate response to SARS-CoV2 vaccination.
A recent study evaluates the immune responses elicited by COVID-19 vaccines in infliximab- or vedolizumab-treated IBD patients.
Despite clear directives outlined in the updated guidelines published by the American College of Rheumatology/National Psoriasis Foundation (ACR/NPF) in 2018, there is limited data regarding medication use in real-world clinical practice and patient medication preferences for the treatment of psoriatic arthritis (PsA).
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear to have an even more severely impeded vaccine response.
A new study discusses risk factors for the failure of seroconversion following full vaccination with the COVID-19 Pfizer vaccine.
Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.
COVID-19 vaccination elicited antibody responses in nearly nine out of 10 people with weakened immune systems, although their responses were only about one-third as strong as those mounted by healthy people, according to a study by researchers at Washington University School of Medicine in St. Louis.
The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen.
A range of evidence-based resources are now available from the Targeted Therapies Alliance to assist dermatologists and their patients in shared decision making in the treatment of plaque psoriasis.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.